Results 251 to 260 of about 10,350,043 (423)

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

In silico λ-dynamics predicts protein binding specificities to modified RNAs. [PDF]

Nucleic Acids Res
Angelo M, Zhang W, Vilseck JZ, Aoki ST.
europepmc   +1 more source

A Rigorous Framework for Calculating Protein-Protein Binding Affinities in Membranes. [PDF]

J Chem Theory Comput, 2023
Blazhynska M, Gumbart JC, Chen H, Tajkhorshid E, Roux B, Chipot C.   +5 more
europepmc   +1 more source

Physicochemical Studies on the Binding of Chemicals with Proteins. VIII. : The Binding of Phenoxazone Compound with Serum Albumin

, 1967
Masayuki Nakagaki, Hiroshi Terada
openalex   +2 more sources

THE IN VITRO RED BLOOD CELL UPTAKE OF C14-CORTISOL; STUDIES OF PLASMA PROTEIN BINDING OF CORTISOL IN NORMAL AND ABNORMAL STATES* [PDF]

, 1962
Robert V. Farese, John E. Plager
openalex   +1 more source

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

Molecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen, Chung‐Teng Wang, Jia‐Ming Chang, Ai‐Li Shiau, Gia‐Shing Shieh, Yau‐Lin Tseng, Yi‐Ting Yen, Tang‐Hsiu Huang, Li‐Hsin Cheng, Yu‐Chih Wu, Chao‐Liang Wu, Bing‐Hua Su, Pensee Wu   +12 more
wiley   +1 more source

Intracellular Protein Binding of Zr-89 Oxine Cell Labeling for PET Cell Tracking Studies. [PDF]

Pharmaceutics
Nyong E, Kurebayashi Y, Asiedu KO, Choyke PL, Sato N.   +4 more
europepmc   +1 more source

SELECTIVE BINDING OF ZINC BY BASIC PROTEINS OF THE HELA CELL NUCLEOLUS [PDF]

, 1965
George P. Studzinski
openalex   +1 more source

Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles

Molecular Oncology, EarlyView.
Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.
Jeffrey A. Ma, Sophia M. Orbach, Kate V. Griffin, Kathryn Kang, Yining Zhang, Rebecca S. Pereles, Ian A. Schrack, Guillermo Escalona, Jacqueline S. Jeruss, Lonnie D. Shea   +9 more
wiley   +1 more source

A Sequential Ultrafiltration Method to Enhance the Accuracy and Throughput in Plasma Protein Binding Tests. [PDF]

Pharmaceutics
Jeon SH, Kim MC, Lee H, Oh JH, Kim HS, Lee H, Park T, Lee YJ.   +7 more
europepmc   +1 more source